Mon, Apr 21, 2014, 5:17 AM EDT - U.S. Markets open in 4 hrs 13 mins

Recent

% | $
Quotes you view appear here for quick access.

Affymax, Inc. (AFFY) Message Board

  • misskellyfitz misskellyfitz Mar 9, 2013 5:27 PM Flag

    The Iron Sucrose administered at the same time the ESA OMONTYS is administered could have caused anaphylactic shock

    support drug for OMONTYS = Venofer

    Venofer safety disclaimer: Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Venofer

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Found this in less than 5 minutes on Venofer:
      Warnings and Precautions

      Hypersensitivity Reactions

      Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Venofer. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. If hypersensitivity reactions or signs of intolerance occur during administration, stop Venofer immediately. Monitor patients for signs and symptoms of hypersensitivity during and after Venofer administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Venofer when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. Most reactions associated with intravenous iron preparations occur within 30 minutes of the completion of the infusion

      Sentiment: Strong Buy

    • Venofer® (iron sucrose injection, USP) is contraindicated in patients with known hypersensitivity to Venofer®. Do not administer Venofer® to patients with evidence of iron overload.

      IMPORTANT SAFETY INFORMATION

      Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Venofer® (iron sucrose injection, USP). Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. If hypersensitivity reactions or signs of intolerance occur during administration, stop Venofer® immediately. Monitor patients for signs and symptoms of hypersensitivity during and after Venofer® administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Venofer® when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions.

      Source:Venofer® Patient Assistance/Venofer Website

 
AFFY
0.634+0.020(+1.67%)Apr 17 3:57 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
AstraZeneca PLC
NYSEThu, Apr 17, 2014 4:00 PM EDT
Snap-on Inc.
NYSEThu, Apr 17, 2014 4:01 PM EDT